SCHEMBL19355307

SCHEMBL19355307

CCNc1ncc(-c2cc(NCCc3cccc4c(C(=O)NC)ccnc34)ncn2)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 10/20 0.39
CYP3A4 P08684 10/20 0.39
CLK4 Q9HAZ1 9/20 0.39
CYP2C19 P33261 8/20 0.39
CYP2D6 P10635 8/20 0.39
ALDH1A1 P00352 7/20 0.39
USP2 O75604 6/20 0.39
HSD17B10 Q99714 6/20 0.39
ALOX15 P16050 4/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
CYP2C9 P11712 2/20 0.38
SLC40A1 Q9NP59 2/20 0.36
PRKDC P78527 2/20 0.35
PDK1 Q15118 1/20 0.35
LMNA P02545 2/20 0.34
MAPT P10636 1/20 0.34
CDC7 O00311 1/20 0.34
ROCK2 O75116 1/20 0.34
MAP4K4 O95819 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19355542 0.92 CYP1A2 (0.39) CYP1A2CYP3A4CLK4CYP2C19CYP2D6
SCHEMBL19819885 0.91 CYP1A2 (0.40) CYP1A2CYP3A4CLK4CYP2C19CYP2D6
SCHEMBL19905362 0.91 CYP1A2 (0.41) CYP1A2CYP3A4CLK4CYP2C19CYP2D6
SCHEMBL19355271 0.91 PRKDC (0.43) CYP1A2CYP3A4CLK4CYP2C19CYP2D6
SCHEMBL19355566 0.90 CYP1A2 (0.38) CYP1A2CYP3A4CLK4CYP2C19CYP2D6
SCHEMBL22838436 0.90 CYP1A2 (0.41) CYP1A2CYP3A4CLK4CYP2C19CYP2D6
SCHEMBL19905089 0.90 CYP1A2 (0.40) CYP1A2CYP3A4CLK4CYP2C19CYP2D6
SCHEMBL19905418 0.90 CYP1A2 (0.38) CYP1A2CYP3A4CLK4CYP2C19CYP2D6
SCHEMBL19905196 0.88 CLK4 (0.39) CYP1A2CYP3A4CLK4CYP2C19CYP2D6
SCHEMBL19355587 0.88 CYP1A2 (0.39) CYP1A2CYP3A4CLK4CYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180193341-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2018-07-12 US disclosed
US-20170258789-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170258789-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK CYP1A2 2215/4885CYP3A4 1759/4885CLK4 383/4885
US-20180193341-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK CYP1A2 2215/4885CYP3A4 1759/4885CLK4 383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.